Patents by Inventor Bruce L. Zamost

Bruce L. Zamost has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8759027
    Abstract: The expression vectors and methods using an E. coli expression system for the large scale production of IL-29 are described. The vectors utilize the IL-29 coding sequence with specific changes in nucleotides in order to optimize codons and mRNA secondary structure for translation in E. coli. Also included are methods of producing, purifying and pegylating an IL-29 polypeptide.
    Type: Grant
    Filed: December 19, 2012
    Date of Patent: June 24, 2014
    Assignee: ZymoGenetics, Inc.
    Inventors: Bruce L. Zamost, Geoffrey F. Lee, Robert M. Dedinsky
  • Publication number: 20120271037
    Abstract: The expression vectors and methods using an E. coli expression system for the large scale production of IL-29 are described. The vectors utilize the IL-29 coding sequence with specific changes in nucleotides in order to optimize codons and mRNA secondary structure for translation in E. coli. Also included are methods of producing, purifying and pegylating an IL-29 polypeptide.
    Type: Application
    Filed: June 5, 2012
    Publication date: October 25, 2012
    Inventors: Bruce L. Zamost, Robert M. Dedinsky
  • Patent number: 8211670
    Abstract: The expression vectors and methods using an E. coli expression system for the large scale production of IL-29 are described. The vectors utilize the IL-29 coding sequence with specific changes in nucleotides in order to optimize codons and mRNA secondary structure for translation in E. coli. Also included are methods of producing, purifying and pegylating an IL-29 polypeptide.
    Type: Grant
    Filed: May 24, 2011
    Date of Patent: July 3, 2012
    Assignee: ZymoGenetics, Inc.
    Inventors: Bruce L. Zamost, Robert M. Dedinsky
  • Publication number: 20120015403
    Abstract: The expression vectors and methods using an E. coli expression system for the large scale production of IL-29 are described. The vectors utilize the IL-29 coding sequence with specific changes in nucleotides in order to optimize codons and mRNA secondary structure for translation in E. coli. Also included are methods of producing, purifying and pegylating an IL-29 polypeptide.
    Type: Application
    Filed: May 24, 2011
    Publication date: January 19, 2012
    Inventors: Bruce L. Zamost, Robert M. Dedinsky
  • Patent number: 7968315
    Abstract: The expression vectors and methods using an E. coli expression system for the large scale production of IL-29 are described. The vectors utilize the IL-29 coding sequence with specific changes in nucleotides in order to optimize codons and mRNA secondary structure for translation in E. coli. Also included are methods of producing, purifying and pegylating an IL-29 polypeptide.
    Type: Grant
    Filed: February 5, 2010
    Date of Patent: June 28, 2011
    Assignee: ZymoGenetics, Inc.
    Inventors: Bruce L. Zamost, Robert M. Dedinsky
  • Publication number: 20100222552
    Abstract: The expression vectors and methods using an E. coli expression system for the large scale production of IL-29 are described. The vectors utilize the IL-29 coding sequence with specific changes in nucleotides in order to optimize codons and mRNA secondary structure for translation in E. coli. Also included are methods of producing, purifying and pegylating an IL-29 polypeptide.
    Type: Application
    Filed: February 5, 2010
    Publication date: September 2, 2010
    Applicant: ZymoGenetics, LLC
    Inventors: Bruce L. Zamost, Robert M. Dedinsky
  • Patent number: 7759092
    Abstract: The expression vectors and methods using an E. coli expression system for the large scale production of IL-29 are described. The vectors utilize the IL-29 coding sequence with specific changes in nucleotides in order to optimize codons and mRNA secondary structure for translation in E. coli. Also included are methods of producing, purifying and pegylating an IL-29 polypeptide.
    Type: Grant
    Filed: August 7, 2009
    Date of Patent: July 20, 2010
    Assignee: ZymoGenetics, LLC
    Inventors: Bruce L. Zamost, Robert M. Dedinsky
  • Patent number: 7745176
    Abstract: The expression vectors and methods using an E. coli expression system for the large scale production of IL-21 are described. The vectors utilize the IL-21 coding sequence with specific changes in nucleotides in order to optimize codons and mRNA secondary structure for translation in E. coli. Using the expression vectors, the IL-21 gene was produced in E. coli to a level of greater than 1 g/L in fed batch fermentation. Also included are OmpT deficient E. coli strains transformed with an IL-21 expression vector.
    Type: Grant
    Filed: October 5, 2006
    Date of Patent: June 29, 2010
    Assignee: ZymoGenetics, Inc.
    Inventors: Bruce L. Zamost, Douglas C. Covert
  • Publication number: 20100003722
    Abstract: The expression vectors and methods using an E. coli expression system for the large scale production of IL-29 are described. The vectors utilize the IL-29 coding sequence with specific changes in nucleotides in order to optimize codons and mRNA secondary structure for translation in E. coli. Also included are methods of producing, purifying and pegylating an IL-29 polypeptide.
    Type: Application
    Filed: August 7, 2009
    Publication date: January 7, 2010
    Applicant: ZymoGenetics, LLC
    Inventors: Bruce L. Zamost, Geoffrey F. Lee, Robert M. Dedinsky
  • Patent number: 7622561
    Abstract: The expression vectors and methods using an E. coli expression system for the large scale production of IL-21 are described. The vectors utilize the IL-21 coding sequence with specific changes in nucleotides in order to optimize codons and mRNA secondary structure for translation in E. coli. Using the expression vectors, the IL-21 gene was produced in E. coli to a level of greater than 1 g/L in fed batch fermentation. Also included are OmpT deficient E. coli strains transformed with an IL-21 expression vector.
    Type: Grant
    Filed: October 5, 2006
    Date of Patent: November 24, 2009
    Assignee: ZymoGenetics, Inc.
    Inventors: Bruce L. Zamost, Hong Y. Liu, Karen S. De Jongh
  • Publication number: 20080096252
    Abstract: The expression vectors and methods using an E. Coli expression system for the large scale production of IL-29 are described. The vectors utilize the IL-29 coding sequence with specific changes in nucleotides in order to optimize codons and mRNA secondary structure for translation in E. coli. Also included are methods of producing, purifying and pegylating an IL-29 polypeptide.
    Type: Application
    Filed: October 4, 2006
    Publication date: April 24, 2008
    Inventors: Bruce L. Zamost, Geoffrey F. Lee, Robert M. Dedinsky
  • Patent number: 7250274
    Abstract: The expression vectors and methods using an E. coli expression system for the large scale production of IL-21 are described. The vectors utilize the IL-21 coding sequence with specific changes in nucleotides in order to optimize codons and mRNA secondary structure for translation in E. coli. Using the expression vectors, the IL-21 gene was produced in E. coli to a level of greater than 1 g/L in fed batch fermentation. Also included are OmpT deficient E. coli strains transformed with an IL-21 expression vector.
    Type: Grant
    Filed: December 12, 2003
    Date of Patent: July 31, 2007
    Assignee: ZymoGenetics, Inc.
    Inventors: Chung Chan, Bruce L. Zamost, Douglas C. Covert, Hong Y. Liu, Karen S. De Jongh, Jeffrey D. Meyer, Susan D. Holderman
  • Patent number: 6750045
    Abstract: A yeast fermentation medium that does not contain yeast cell extract but is comprised of a mixture of oleic acid, lactic acid and palmitic acid. Using this fermentation medium yields of factor XIII were increased 250%.
    Type: Grant
    Filed: July 23, 2002
    Date of Patent: June 15, 2004
    Assignee: ZymoGenetics, Inc.
    Inventor: Bruce L. Zamost
  • Publication number: 20030059925
    Abstract: A yeast fermentation medium that does not contain yeast cell extract but is comprised of a mixture of oleic acid, lactic acid and palmitic acid. Using this fermentation medium yields of factor XIII were increased 250%.
    Type: Application
    Filed: July 23, 2002
    Publication date: March 27, 2003
    Inventor: Bruce L. Zamost
  • Patent number: 6258559
    Abstract: Methylotrophic yeasts are useful hosts for the production of commercially valuable recombinant proteins. However, the development of large-scale cultures of recombinant methylotrophic yeasts has been hindered by the formation of precipitation in culture media. A new soluble minimal medium overcomes this problem. Moreover, new feeding schemes provide cultures of high biomass, which produce biologically active recombinant protein.
    Type: Grant
    Filed: March 21, 2000
    Date of Patent: July 10, 2001
    Assignee: ZymoGenetics, Inc.
    Inventor: Bruce L. Zamost
  • Patent number: 5491087
    Abstract: An isolated arabinofuranosidase from Bacillus stearothermophilus NRRL B-18659, Bacillus stearothermophilus NRRL B-18660 and Bacillus stearothermophilus NRRL B-18661 is disclosed. The arabinofuranosidase has a maximum activity at about pH 6.0 and at about 65.degree. C., maintains at least about 50% of its maximum activity at 70.degree. C. and pH 7.0 after 80 minutes, and has an isoelectric point of about 4.4. The arabinfuranosidase can be used in a method of hydrolyzing xylan present in wood pulp at temperatures of at least about 60.degree. C. and a pH of at least about 7.0. The arabinofuranosidase is used along with at least two xylanases and a xylosidase isolated from the above Bacillus stearothermophilus strains.
    Type: Grant
    Filed: April 6, 1995
    Date of Patent: February 13, 1996
    Assignee: Novo Nordisk A/S
    Inventors: Bruce L. Zamost, Dana D. Elm
  • Patent number: 5489526
    Abstract: An isolated xylosidase from Bacillus stearothermophilus NRRL B-18659, Bacillus stearothermophilus NRRL B-18660 and Bacillus stearothermophilus NRRL B-18661 is disclosed. The xylosidase has a maximum activity at about pH 6.0 and at about 75.degree. C., maintains at least about 60% of its maximum activity at about 65.degree. C. and pH 7 after 4 hours, is resistant to end-product inhibition maintaining over 75% of maximum activity in the presence of 1 molar xylose and has an isoelectric point of about 5.0. The xylosidase can be used in a method of hydrolyzing xylan present in wood pulp at temperatures of at least about 60.degree. C. and a pH of at least about 7.0. The xylosidase is used along with at least two xylanases and an arabinofuranosidase isolated from the above Bacillus stearothermophilus strains.
    Type: Grant
    Filed: April 6, 1995
    Date of Patent: February 6, 1996
    Assignee: Novo Nordisk A/S
    Inventors: Bruce L. Zamost, Dana D. Elm